• Home
  • Cardiovascular diseases Publications

Cardiovascular diseases Publications

Cardiovascular diseases Publications

  • Persisting gender differences and attenuating age differences in cardiovascular drug use for prevention and treatment of coronary heart disease, 1998-2010.Abstract

    BACKGROUND: Evidence on recent time trends in age-gender differences in cardiovascular drug use is scarce. We studied time trends in age-gender-specific cardiovascular drug use for primary prevention, secondary prevention, and in-hospital treatmentof coronary heart disease. METHODS AND RESULTS: The PHARMO database was used for record linkage of drug dispensing, hospitalization, and population data to identify drug use between 1998 and 2010 in 1 203 290 persons >/=25 years eligible for primary prevention, 84 621 persons hospitalized for an acute coronary syndrome (ACS), and 15 651 persons eligible for secondary prevention

    Koopman C, Vaartjes I, Heintjes EM, Spiering W, van Dis I, Herings RM, Bots ML. Eur Heart J. 2013 Nov; 34 (41): 3198-205.
  • Pulmonary embolism, myocardial infarction, and ischemic stroke in lung cancer patients: results from a longitudinal study.Abstract

    PURPOSE: In this cohort study, the rates of pulmonary embolism (PE), myocardial infarction (MI), and ischemic stroke (IS) before and after lung cancer (LC) diagnosis were compared to cancer-free controls. METHODS: Patients with LC during 2000-2007ere selected from PALGA, the Dutch Pathology Registry, and linked to the PHARMO medical record linkage system, including drug use and hospitalizations of 3 million inhabitants in the Netherlands

    van Herk-Sukel MP, Shantakumar S, Penning-van Beest FJ, Kamphuisen PW, Majoor CJ, Overbeek LI, Herings RM. Lung. 2013 Oct; 191 (5): 501-9.
  • Statin treatment and the risk of recurrent pulmonary embolism.Abstract

    AIMS: Patients with idiopathic venous thromboembolism (VTE) have a high recurrence risk during and after stopping anticoagulant treatment. Several studies suggest that treatment with statins reduces the incidence of a first episode of VTE, but dataon the effects in patients with a previous episode are lacking

    Biere-Rafi S, Hutten BA, Squizzato A, Ageno W, Souverein PC, de Boer A, Gerde s VE, Buller HR, Kamphuisen PW. Eur Heart J. 2013 Jun; 34 (24): 1800-6.
  • Use of oral glucocorticoids and the risk of pulmonary embolism: a population-based case-control study.Abstract

    BACKGROUND: Recently, endogenous glucocorticoid excess has been identified as a risk factor for VTE. Whether exogenous use of glucocorticoids is associated with an increased risk of VTE is unclear. We aimed to quantify the risk of symptomatic pulmoary embolism (PE) in patients using corticosteroids. METHODS: A case-control study using the PHARMO Record Linkage System, a Dutch population-based pharmacy registry, was conducted

    Stuijver DJ, Majoor CJ, van Zaane B, Souverein PC, de Boer A, Dekkers OM, Buller HR, Gerde s VE. Chest. 2013 May; 143 (5): 1337-42.
  • INR control calculation: comparison of Dutch and international methods.Abstract

    Results of trials with new oral anticoagulant drugs and vitamin K antagonists (VKA) might not be directly applicable to Dutch clinical practice due to the high level of control of anticoagulation in the Netherlands. In addition, the Dutch method foassessing anticoagulation control uses cross-sectional international normalised ratio (INR) test results while the method used in the trials is based on person-time

    Bezemer ID, Roemer WH, Penning-van Beest FJ, van Eekelen E, Kramer MH. Neth J Med. 2013 May; 71 (4): 194-8.
  • Increased risk of sudden cardiac arrest in obstructive pulmonary disease: a case-control study.Abstract

    BACKGROUND: We aimed to determine whether (1) patients with obstructive pulmonary disease (OPD) have an increased risk of sudden cardiac arrest (SCA) due to ventricular tachycardia or fibrillation (VT/VF), and (2) the SCA risk is mediated by cardioascular risk-profile and/or respiratory drug use. METHODS: A community-based case-control study was performed, with 1310 cases of SCA of the ARREST study and 5793 age, sex and SCA-date matched non-SCA controls from the PHARMO database

    Warnier MJ, Blom MT, Bardai A, Berdowksi J, Souverein PC, Hoes AW, Rutten FH, de Boer A, Koster RW, DeBruin ML, Tan HL. PLoS One. 2013 8 (6): e65638.
  • Drug-induced acute myocardial infarction: identifying ‘prime suspects’ from electronic healthcare records-based surveillance system.Abstract

    BACKGROUND: Drug-related adverse events remain an important cause of morbidity and mortality and impose huge burden on healthcare costs. Routinely collected electronic healthcare data give a good snapshot of how drugs are being used in ‘real-world’settings. OBJECTIVE: To describe a strategy that identifies potentially drug-induced acute myocardial infarction (AMI) from a large international healthcare data network

    Coloma PM, Schuemie MJ, Trifiro G, Furlong L, van Mulligen E, Bauer-Mehren A, Avillach P, Kors J, Sanz F, Mestres J, Oliveira JL, Boyer S, Helgee EA, Molokhia M, Matthews J, Prieto-Merino D, Gini R, Herings R, Mazzaglia G, Picelli G, Scotti L, Peder sen L, van der Lei J, Sturkenboom M, consortium Eu-Adr. PLoS One. 2013 8 (8): e72148.
  • Risk of myocardial infarction in Dutch patients following discharge for total hip/knee replacement and matched controls: a population-based cohort study.Abstract


    Klop C, DeVries F, Lalmohamed A, Leufkens HGM, Bijlsma JWJ, Welsing PMJ. OA Epidemiology. 2013 1 (1): 6.
  • Use of rivastigmine or galantamine and risk of adverse cardiac events: a database study from the Netherlands.Abstract

    BACKGROUND: Two cholinesterase inhibitors (ChEIs), rivastigmine and galantamine, are used to treat Alzheimer disease in the Netherlands. Several adverse cardiac events have been reported for these medications. OBJECTIVE: We aimed to assess if the ue of ChEIs increased the risk of cardiac events in the Netherlands

    Kroger E, Berkers M, Carmichael PH, Souverein P, van Marum R, Egberts T. Am J Geriatr Pharmacother. 2012 Dec; 10 (6): 373-80.
  • Cholesterol Level Goal Attainment with Statins: Clinical Management Guideline Recommendations versus Management in Actual Clinical Practice.Abstract

    STUDY OBJECTIVES: To compare the cholesterol level goal attainment rates in patients receiving simvastatin doses recommended in clinical practice guidelines and simvastatin doses most frequently prescribed in clinical practice versus other statinst various dose levels, and to assess statin adherence rates in patients receiving all statins

    Heintjes EM, Penning-van Beest FJ, Plat AW, Meerding WJ, Webb K, Sturkenboom MC, Herings RM. Pharmacotherapy. 2012 Jul; 32 (7): 631-41.